Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer
Background. Transarterial chemoembolization (TACE) has been investigated in patients with liver metastases from colorectal cancer (LMCRC). Limited experience and available data suggest that TACE can achieve disease stabilization or improvement, even in heavily pretreated patients. Methods. Patients...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2015/715102 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832547588059955200 |
|---|---|
| author | M. Stutz A. Mamo D. Valenti A. Hausvater T. Cabrera P. Metrakos P. Chaudhury G. Steacy E. Garoufalis P. Kavan |
| author_facet | M. Stutz A. Mamo D. Valenti A. Hausvater T. Cabrera P. Metrakos P. Chaudhury G. Steacy E. Garoufalis P. Kavan |
| author_sort | M. Stutz |
| collection | DOAJ |
| description | Background. Transarterial chemoembolization (TACE) has been investigated in patients with liver metastases from colorectal cancer (LMCRC). Limited experience and available data suggest that TACE can achieve disease stabilization or improvement, even in heavily pretreated patients. Methods. Patients with LMCRC, ECOG 0–2, who failed at least 1 line of systemic chemotherapy, received embolizations with 2 mL of microspheres preloaded with 100 mg of irinotecan. Beads were delivered selectively into hepatic arteries. Primary endpoint was overall survival (OS), analyzed using the Kaplan-Meier method. Secondary endpoint was safety, assessed using CTCAE version 4.0. Results. 27 patients were treated using DEBIRI. Patient median age was 57 years (range was 45–82 years). The median number of total embolizations was 1.3 (range 1–3). The median OS was 5.4 months (95% CI; 1.1–22.7 months). The most reported postembolization events were nausea (8/27), vomiting (6/27), right upper quadrant pain (16/27), fatigue (9/27), and the development of ascites (6/27). 5/26 patients required hospitalization after TACE for severe pain. Hospitalization was also required for 1 case of allergic reaction and 1 case of infection. Conclusion. Our data suggest that TACE with DEBIRI could be efficacious in a palliative setting for patients with LMCRC, but they do not necessarily support routine use in clinical practice. |
| format | Article |
| id | doaj-art-92889b1b79494dffa7d38d6be6529ec7 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-92889b1b79494dffa7d38d6be6529ec72025-02-03T06:44:16ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/715102715102Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal CancerM. Stutz0A. Mamo1D. Valenti2A. Hausvater3T. Cabrera4P. Metrakos5P. Chaudhury6G. Steacy7E. Garoufalis8P. Kavan9Segal Cancer Centre, JGH, McGill University, CanadaSegal Cancer Centre, JGH, McGill University, CanadaRadiology, McGill University Health Centre, CanadaSegal Cancer Centre, JGH, McGill University, CanadaRadiology, McGill University Health Centre, CanadaHepatobiliary Surgery, McGill University Health Centre, CanadaHepatobiliary Surgery, McGill University Health Centre, CanadaHepatobiliary Surgery, McGill University Health Centre, CanadaOncology, McGill University Health Centre, CanadaSegal Cancer Centre, JGH, McGill University, CanadaBackground. Transarterial chemoembolization (TACE) has been investigated in patients with liver metastases from colorectal cancer (LMCRC). Limited experience and available data suggest that TACE can achieve disease stabilization or improvement, even in heavily pretreated patients. Methods. Patients with LMCRC, ECOG 0–2, who failed at least 1 line of systemic chemotherapy, received embolizations with 2 mL of microspheres preloaded with 100 mg of irinotecan. Beads were delivered selectively into hepatic arteries. Primary endpoint was overall survival (OS), analyzed using the Kaplan-Meier method. Secondary endpoint was safety, assessed using CTCAE version 4.0. Results. 27 patients were treated using DEBIRI. Patient median age was 57 years (range was 45–82 years). The median number of total embolizations was 1.3 (range 1–3). The median OS was 5.4 months (95% CI; 1.1–22.7 months). The most reported postembolization events were nausea (8/27), vomiting (6/27), right upper quadrant pain (16/27), fatigue (9/27), and the development of ascites (6/27). 5/26 patients required hospitalization after TACE for severe pain. Hospitalization was also required for 1 case of allergic reaction and 1 case of infection. Conclusion. Our data suggest that TACE with DEBIRI could be efficacious in a palliative setting for patients with LMCRC, but they do not necessarily support routine use in clinical practice.http://dx.doi.org/10.1155/2015/715102 |
| spellingShingle | M. Stutz A. Mamo D. Valenti A. Hausvater T. Cabrera P. Metrakos P. Chaudhury G. Steacy E. Garoufalis P. Kavan Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer Gastroenterology Research and Practice |
| title | Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer |
| title_full | Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer |
| title_fullStr | Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer |
| title_full_unstemmed | Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer |
| title_short | Real-Life Report on Chemoembolization Using DEBIRI for Liver Metastases from Colorectal Cancer |
| title_sort | real life report on chemoembolization using debiri for liver metastases from colorectal cancer |
| url | http://dx.doi.org/10.1155/2015/715102 |
| work_keys_str_mv | AT mstutz reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT amamo reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT dvalenti reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT ahausvater reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT tcabrera reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT pmetrakos reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT pchaudhury reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT gsteacy reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT egaroufalis reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer AT pkavan reallifereportonchemoembolizationusingdebiriforlivermetastasesfromcolorectalcancer |